{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:15:31Z","timestamp":1792883731427,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.blre.2025.101268","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T19:04:27Z","timestamp":1737745467000},"page":"101268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies"],"prefix":"10.1016","volume":"70","author":[{"given":"Sofija","family":"Kozarac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojin","family":"Vukovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Antic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.blre.2025.101268_bb0005","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3390\/cancers16112011","article-title":"Treatment sequencing in chronic lymphocytic leukemia in 2024: where we are and where we are headed","volume":"16","author":"Fresa","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.blre.2025.101268_bb0010","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101268_bb0015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN guidelines\u00ae insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 3.2022: featured updates to the NCCN guidelines","volume":"20","author":"Wierda","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"S2","key":"10.1016\/j.blre.2025.101268_bb0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.26677","article-title":"Management of front line chronic lymphocytic leukemia","volume":"97","author":"Kutsch","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.blre.2025.101268_bb0030","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.blre.2025.101268_bb0040","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2025.101268_bb0045","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101268_bb0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-021-00467-7","article-title":"Ibrutinib combinations in CLL therapy: scientific rationale and clinical results","volume":"11","author":"Timofeeva","year":"2021","journal-title":"Blood Cancer J"},{"issue":"29","key":"10.1016\/j.blre.2025.101268_bb0055","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.blre.2025.101268_bb0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3324\/haematol.2018.192328","article-title":"Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2","volume":"103","author":"Barr","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101268_bb0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0070","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2025.101268_bb0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.blre.2025.101268_bb0080","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2025.101268_bb0085","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","article-title":"Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells","volume":"23","author":"Patel","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2025.101268_bb0090","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond Ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"10.1016\/j.blre.2025.101268_bb0095","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"issue":"10232","key":"10.1016\/j.blre.2025.101268_bb0100","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14728214.2020.1724282","article-title":"Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib","volume":"25","author":"Molica","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0110","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus Investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.blre.2025.101268_bb0115","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2025.101268_bb0120","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.blre.2025.101268_bb0125","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0130","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.blre.2025.101268_bb0135","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3390\/cancers15092596","article-title":"The evolution of therapies targeting Bruton tyrosine kinase for the treatment of chronic lymphocytic Leukaemia: future perspectives","volume":"15","author":"Eyre","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101268_bb0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood-2023-182397","article-title":"Long-term outcomes in chronic lymphocytic leukemia treated with Ibrutinib: 10-year follow-up of a phase 2 study","volume":"142","author":"Itsara","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101268_bb0145","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia","volume":"5(5):570","author":"Quartermaine","year":"2023","journal-title":"JACC: CardioOncology State-of-the-Art Review JACC: CardioOncology"},{"issue":"11","key":"10.1016\/j.blre.2025.101268_bb0150","article-title":"Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States","volume":"27","author":"Chatterjee","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2025.101268_bb0155","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1182\/blood-2023-177939","article-title":"Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting","volume":"142","author":"Manzoor","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101268_bb0160","series-title":"NCI_CTCAE_5 (common terminology criteria for adverse events 5.0) - synopsis [internet]","author":"UMLS Metathesaurus","year":"2024"},{"issue":"26","key":"10.1016\/j.blre.2025.101268_bb0165","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus Chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.blre.2025.101268_bb0170","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2025.101268_bb0175","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","article-title":"Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study","volume":"175","author":"Thompson","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0180","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clml.2016.09.010","article-title":"Risk of atrial fibrillation and bleeding diathesis associated with Ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials","volume":"17","author":"Yun","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.blre.2025.101268_bb0185","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.blre.2025.101268_bb0190","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1080\/10428194.2017.1375110","article-title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors","volume":"59","author":"Tang","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0200","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes","volume":"100","author":"Archibald","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0205","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/10428194.2017.1339874","article-title":"Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management","volume":"59","author":"Thorp","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1016\/j.blre.2025.101268_bb0210","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2025.101268_bb0215","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3389\/fphys.2013.00416","article-title":"Src as the link between inflammation and cancer","volume":"4","author":"Liu","year":"2014","journal-title":"Front Physiol"},{"key":"10.1016\/j.blre.2025.101268_bb0220","doi-asserted-by":"crossref","first-page":"1150569","DOI":"10.3389\/fcvm.2023.1150569","article-title":"Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications","volume":"10","author":"Kwok","year":"2023","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101268_bb0225","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"37","key":"10.1016\/j.blre.2025.101268_bb0230","doi-asserted-by":"crossref","first-page":"24857","DOI":"10.1074\/jbc.M109.003186","article-title":"Critical role of nuclear calcium\/calmodulin-dependent protein kinase IIdeltaB in cardiomyocyte survival in cardiomyopathy","volume":"284","author":"Little","year":"2009","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.blre.2025.101268_bb0235","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"issue":"25","key":"10.1016\/j.blre.2025.101268_bb0240","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1161\/CIRCULATIONAHA.120.052047","article-title":"Cardio-oncology: a win-win situation: how solving the mystery of an Ibrutinib off-target effect reveals new insights into atrial fibrillation mechanisms","volume":"142","author":"Awan","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.blre.2025.101268_bb0245","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.blre.2025.101268_bb0250","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.blre.2025.101268_bb0255","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0260","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.blre.2025.101268_bb0265","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach","volume":"102","author":"de Weerdt","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101268_bb0270","author":"Vrontikis"},{"issue":"26","key":"10.1016\/j.blre.2025.101268_bb0275","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101268_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"de Jong","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"15","key":"10.1016\/j.blre.2025.101268_bb0285","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa1001337","article-title":"Lenient versus strict rate control in patients with atrial fibrillation","volume":"362","author":"Van Gelder","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2025.101268_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2012.11.024","article-title":"Body mass index and adverse events in patients with incident atrial fibrillation","volume":"126","author":"Overvad","year":"2013","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.blre.2025.101268_bb0295","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCEP.113.001244","article-title":"Physical activity, obesity, weight change, and risk of atrial fibrillation: the atherosclerosis risk in communities study","volume":"7","author":"Huxley","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"20","key":"10.1016\/j.blre.2025.101268_bb0300","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","article-title":"Obesity and the risk of new-onset atrial fibrillation","volume":"292","author":"Wang","year":"2004","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.blre.2025.101268_bb0305","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1161\/HYPERTENSIONAHA.117.08934","article-title":"Atrial fibrillation and hypertension","volume":"70","author":"Dzeshka","year":"2017","journal-title":"Hypertension"},{"issue":"22","key":"10.1016\/j.blre.2025.101268_bb0310","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101268_bb0315","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/heartjnl-2021-319110","article-title":"Association between ibrutinib treatment and hypertension","volume":"108","author":"Lee","year":"2022","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0320","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","article-title":"Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation","volume":"15","author":"Chen","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.blre.2025.101268_bb0325","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0330","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1057385","article-title":"Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells","volume":"5","author":"Natarajan","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.blre.2025.101268_bb0335","author":"American College of Cardiology [Internet]. [cited 2024]"},{"key":"10.1016\/j.blre.2025.101268_bb0345","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1741-7015-10-33","article-title":"Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis","volume":"10","author":"Fretheim","year":"2012","journal-title":"BMC Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0350","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1097\/HJH.0000000000000379","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels--overview and meta-analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J Hypertens"},{"issue":"18","key":"10.1016\/j.blre.2025.101268_bb0355","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101268_bb0360","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following Ibrutinib initiation for Cancer immunotherapy","volume":"72","author":"Guha","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0365","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.19469","article-title":"Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib","volume":"205","author":"Sharman","year":"2024","journal-title":"Br J Haematol"},{"issue":"20","key":"10.1016\/j.blre.2025.101268_bb0370","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0375","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1080\/10428194.2018.1482546","article-title":"Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware","volume":"59","author":"Tam","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0380","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1080\/10428194.2018.1457149","article-title":"Ibrutinib-associated ventricular arrhythmia in the FDA adverse event reporting system","volume":"59","author":"Cheng","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1016\/j.blre.2025.101268_bb0385","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101268_bb0390","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00280-017-3471-x","article-title":"Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study","volume":"80","author":"de Jong","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.blre.2025.101268_bb0395","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0400","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2025.101268_bb0405","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4065\/84.3.289","article-title":"Ventricular tachycardia and sudden cardiac death","volume":"84","author":"Koplan","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.blre.2025.101268_bb0410","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1016\/j.jacc.2006.07.010","volume":"48","author":"European Heart Rhythm Association, Heart Rhythm Society","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.blre.2025.101268_bb0415","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pcad.2008.06.003","article-title":"Epidemiology of sudden cardiac death: clinical and research implications","volume":"51","author":"Chugh","year":"2008","journal-title":"Prog Cardiovasc Dis"},{"issue":"11","key":"10.1016\/j.blre.2025.101268_bb0420","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3390\/jcm11113233","article-title":"Pharmacologic Management for Ventricular Arrhythmias: overview of anti-arrhythmic drugs","volume":"11","author":"Larson","year":"2022","journal-title":"J Clin Med"},{"issue":"40","key":"10.1016\/j.blre.2025.101268_bb0425","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.blre.2025.101268_bb0430","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s10840-022-01400-z","article-title":"Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature","volume":"66","author":"Fazal","year":"2023","journal-title":"J Interv Card Electrophysiol"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0435","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2025.101268_bb0440","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"31","key":"10.1016\/j.blre.2025.101268_bb0445","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with Ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0450","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0455","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.blre.2025.101268_bb0460","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients","volume":"107","author":"Brown","year":"2022","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.blre.2025.101268_bb0465","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2025.101268_bb0470","author":"Drugs.com [Internet]"},{"issue":"6","key":"10.1016\/j.blre.2025.101268_bb0480","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.blre.2025.101268_bb0485","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101268_bb0490","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0495","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.blre.2025.101268_bb0500","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101268_bb0505","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis","volume":"184","author":"Brown","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0510","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.14660","article-title":"Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib","volume":"178","author":"Jones","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0515","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3324\/haematol.2016.144576","article-title":"Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group","volume":"101","author":"Winqvist","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2025.101268_bb0520","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Warfarin Antiplatelet Vascular Evaluation Trial Investigators","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2025.101268_bb0525","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0530","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0540","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3324\/haematol.2018.193391","article-title":"Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI","volume":"103","author":"Nicolson","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0545","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","volume":"1","author":"Caron","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2025.101268_bb0550","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2025.101268_bb0555","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding","volume":"36","author":"Boriani","year":"2018","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.blre.2025.101268_bb0560","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding; pathogenesis, management, and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0565","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaccao.2023.02.001","article-title":"Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients","volume":"5","author":"Diamond","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"13","key":"10.1016\/j.blre.2025.101268_bb0570","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular Toxicities Associated With Ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0575","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1080\/21655979.2021.1974810","article-title":"Ibrutinib ameliorates cerebral ischemia\/reperfusion injury through autophagy activation and PI3K\/Akt\/mTOR signaling pathway in diabetic mice","volume":"12","author":"Jin","year":"2024","journal-title":"Bioengineered"},{"key":"10.1016\/j.blre.2025.101268_bb0580","first-page":"8","article-title":"Pericardial effusion in oncological patients: current knowledge and principles of management","volume":"10","author":"Mori","year":"2024","journal-title":"Cardiooncology"},{"issue":"20","key":"10.1016\/j.blre.2025.101268_bb0585","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.3390\/cancers16203466","article-title":"Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment","volume":"16","author":"Lorenzo-Esteller","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.blre.2025.101268_bb0590","doi-asserted-by":"crossref","first-page":"2312182","DOI":"10.1155\/2024\/2312182","article-title":"Pericarditis and Cardiac Tamponade in Patients Treated with First and Second Generation Bruton Tyrosine Kinase Inhibitors: An Underappreciated Risk","volume":"2024","author":"Erblich","year":"2024","journal-title":"Case Rep Hematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101268_bb0595","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0600","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0605","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clinthera.2023.11.014","article-title":"Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis","volume":"46","author":"Proskuriakova","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.blre.2025.101268_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.769315","article-title":"Safety Profile of Ibrutinib: An Analysis of the WHO Pharmacovigilance Database","volume":"12","author":"Allouchery","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.blre.2025.101268_bb0615","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11523-009-0110-4","article-title":"Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors","volume":"4","author":"Kelly","year":"2009","journal-title":"Target Oncol"},{"issue":"26","key":"10.1016\/j.blre.2025.101268_bb0620","first-page":"3137","article-title":"Pirtobrutinib: a new hope for patients with BTK inhibitor\u2013refractory lymphoproliferative disorders","volume":"141","author":"Thompson","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0625","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2025.101268_bb0630","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","article-title":"Pirtobrutinib: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"10277","key":"10.1016\/j.blre.2025.101268_bb0635","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.blre.2025.101268_bb0640","first-page":"92","article-title":"Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I\/II BRUIN trial","volume":"110","author":"Shah","year":"2024","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2025.101268_bb0645","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3324\/haematol.2022.281402","article-title":"Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib","volume":"108","author":"Bye","year":"2022","journal-title":"Haematologica"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2500013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2500013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:37:47Z","timestamp":1740112667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X2500013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":126,"alternative-id":["S0268960X2500013X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101268","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BTKi-induced cardiovascular toxicity in CLL: Risk mitigation and management strategies","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101268"}}